Work

Phase 1 study of the PSMA-targeted small-molecule drug conjugate EC1169 in patients with metastatic castrate-resistant prostate cancer (mCRPC).

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.5038

Authors: Michael J. Morris, Nicholas J. Vogelzang, Oliver Sartor, Alison Armour, Michael Groaning, Adam Robarts, Daniel Peter Petrylak, Anthony W. Tolcher, Michael S. Gordon, Hani M. Babiker

Institutions: Memorial Sloan Kettering Cancer Center, Comprehensive Cancer Centers of Nevada, Tulane University, Endocyte (United States), Yale University, South Texas Accelerated Research Therapeutics, HonorHealth, Pinnacle Oncology Hematology, University of Arizona Cancer Center

Language: English

Topic: Prostate Cancer Treatment and Research

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4243349391

Cites:

Cited by: 10

Related to: 10